Kisspeptin-10 Mitigates α-Synuclein-Mediated Mitochondrial Apoptosis in SH-SY5Y-Derived Neurons via a Kisspeptin Receptor-Independent Manner.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Kisspeptins*/genetics ; Kisspeptins*/pharmacology ; Kisspeptins*/metabolism ; Neuroblastoma*/metabolism; Humans ; alpha-Synuclein/genetics ; alpha-Synuclein/metabolism ; Apoptosis ; Neurons/metabolism

The hypothalamic neurohormone kisspeptin-10 (KP-10) was inherently implicated in cholinergic pathologies when aberrant fluctuations of expression patterns and receptor densities were discerned in neurodegenerative micromilieus. That said, despite variable degrees of functional redundancy, KP-10, which is biologically governed by its cognate G-protein-coupled receptor, GPR54, attenuated the progressive demise of α-synuclein (α-syn)-rich cholinergic-like neurons. Under explicitly modeled environments, in silico algorithms further rationalized the surface complementarities between KP-10 and α-syn when KP-10 was unambiguously accommodated in the C-terminal binding pockets of α-syn. Indeed, the neuroprotective relevance of KP-10's binding mechanisms can be insinuated in the amelioration of α-syn-mediated neurotoxicity; yet it is obscure whether these extenuative circumstances are contingent upon prior GPR54 activation. Herein, choline acetyltransferase (ChAT)-positive SH-SY5Y neurons were engineered ad hoc to transiently overexpress human wild-type or E46K mutant α-syn while the mitigation of α-syn-induced neuronal death was ascertained via flow cytometric and immunocytochemical quantification. Recapitulating the specificity observed on cell viability, exogenously administered KP-10 (0.1 µM) substantially suppressed wild-type and E46K mutant α-syn-mediated apoptosis and mitochondrial depolarization in cholinergic differentiated neurons. In particular, co-administrations with a GPR54 antagonist, kisspeptin-234 (KP-234), failed to abrogate the robust neuroprotection elicited by KP-10, thereby signifying a GPR54 dispensable mechanism of action. Consistent with these observations, KP-10 treatment further diminished α-syn and ChAT immunoreactivity in neurons overexpressing wild-type and E46K mutant α-syn. Overall, these findings lend additional credence to the previous notion that KP-10's binding zone may harness efficacious moieties of neuroprotective intent.

J Neurodegener Dis. 2013;2013:879710. (PMID: 26317001)
Adv Exp Med Biol. 2013;784:159-86. (PMID: 23550006)
Acta Neuropathol. 2010 Nov;120(5):633-9. (PMID: 20721565)
J Biol Chem. 2018 Mar 23;293(12):4486-4497. (PMID: 29382725)
J Neurol Sci. 1977 Nov;34(2):247-65. (PMID: 144789)
ACS Chem Neurosci. 2019 Apr 17;10(4):1915-1922. (PMID: 30253092)
Mol Neurodegener. 2021 Sep 9;16(1):63. (PMID: 34503546)
Physiology (Bethesda). 2010 Aug;25(4):207-17. (PMID: 20699467)
Eur J Med Chem. 2014 Dec 17;88:42-54. (PMID: 25081642)
Endocr Rev. 2009 Oct;30(6):713-43. (PMID: 19770291)
J Neurol Sci. 2011 Nov 15;310(1-2):90-5. (PMID: 21774947)
J Neurochem. 1994 May;62(5):1653-63. (PMID: 8158117)
Nat Rev Neurosci. 2013 Jan;14(1):38-48. (PMID: 23254192)
ACS Chem Neurosci. 2015 Dec 16;6(12):1930-40. (PMID: 26378986)
Brain Res. 2017 Sep 1;1670:173-184. (PMID: 28652219)
Brain Res. 2010 Dec 10;1364:81-9. (PMID: 20858467)
Cell Biosci. 2021 Nov 19;11(1):196. (PMID: 34798911)
Nat Rev Urol. 2016 Jan;13(1):21-32. (PMID: 26620614)
Mol Cell Endocrinol. 2010 Jan 27;314(2):164-9. (PMID: 19464345)
PLoS One. 2017 Jun 26;12(6):e0179156. (PMID: 28650956)
Free Radic Biol Med. 2021 Aug 1;171:99-111. (PMID: 33989759)
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1761-6. (PMID: 15665093)
J Biol Chem. 2001 Sep 14;276(37):34631-6. (PMID: 11457843)
Hum Mol Genet. 2001 Apr 15;10(9):919-26. (PMID: 11309365)
Pathol Int. 1999 Nov;49(11):921-37. (PMID: 10594838)
Am J Pathol. 2000 Aug;157(2):401-10. (PMID: 10934145)
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73. (PMID: 9600990)
Nature. 1997 Aug 28;388(6645):839-40. (PMID: 9278044)
Neurogenetics. 2016 Jul;17(3):145-57. (PMID: 26948950)
Ann Neurol. 2002 Feb;51(2):145-55. (PMID: 11835370)
Nat Struct Mol Biol. 2008 Jun;15(6):558-66. (PMID: 18511942)
Int J Mol Sci. 2022 May 06;23(9):. (PMID: 35563582)
Hum Reprod Update. 2006 Sep-Oct;12(5):631-9. (PMID: 16731583)
ISRN Neurosci. 2013 Jul 17;2013:253210. (PMID: 24967306)
Ann Neurol. 2004 Feb;55(2):164-73. (PMID: 14755719)
FEMS Yeast Res. 2006 Dec;6(8):1107-16. (PMID: 17156009)
Nat Rev Neurosci. 2005 Jan;6(1):48-56. (PMID: 15611726)
Semin Reprod Med. 2019 Mar;37(2):56-63. (PMID: 31847025)
J Biol Chem. 2004 Jun 25;279(26):26846-57. (PMID: 15096521)
J Neurosci. 2009 Mar 25;29(12):3920-9. (PMID: 19321788)
J Neurochem. 2019 Sep;150(5):577-590. (PMID: 31069800)
Nat Rev Drug Discov. 2017 May 31;16(6):371-373. (PMID: 28559555)
Exp Neurol. 2017 Dec;298(Pt B):225-235. (PMID: 28987463)
ACS Chem Neurosci. 2012 Sep 19;3(9):706-19. (PMID: 23019497)
Am J Pathol. 1998 Apr;152(4):879-84. (PMID: 9546347)
J Neurochem. 2010 Jul;114(2):419-29. (PMID: 20412383)
J Neurol Sci. 1982 Dec;57(2-3):407-17. (PMID: 7161627)
ACS Chem Neurosci. 2014 Jan 15;5(1):30-8. (PMID: 24099687)
Trends Mol Med. 2021 Aug;27(8):807-823. (PMID: 34210598)
Mol Endocrinol. 2009 Dec;23(12):2060-74. (PMID: 19846537)
Neurology. 2006 Dec 12;67(11):1931-4. (PMID: 17159096)
Front Neurosci. 2019 Nov 01;13:1124. (PMID: 31749672)

Keywords: E46K mutant; GPR54; choline acetyltransferase; cholinergic neurons; dementia with Lewy bodies; intrinsic apoptosis; kisspeptin-234; mitochondrial depolarization; neuroprotection

0 (alpha-Synuclein)
0 (KISS1 protein, human)
0 (KISS1R protein, human)
0 (Kisspeptins)
0 (SNCA protein, human)

Date Created: 20230413 Date Completed: 20230415 Latest Revision: 20230415

20231215

PMC10094180

10.3390/ijms24076056

37047030